This study highlights the critical importance of bone marrow (BM)-derived monocyte lineages in enhancing tumor progression and provides evidence for the potential application of THBS1-targeted therapy as an effective treatment for aggressive CRC. This evidence concerns the gene THBS1 and neoplasm.